MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fractyl Health, Inc. - Common Stock (NQ:GUTS)

0.4865 +0.0172 (+3.67%)
Streaming Delayed Price Updated: 1:52 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fractyl Health, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
From DJS Law Group
Via Business Wire
News headline image
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
From The DJS Law Group
Via Business Wire
News headline image
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
MAGA Stocks Undercard: SNYR GUTS MRM MYSE Under $3 To Watch Now….more inside
Via AB Newswire
Topics Economy
News headline image
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces Proposed Public Offering
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story